Growth hormone replacement therapy (GHRT) in children and adolescents: Skeletal impact

Medical and Pediatric Oncology

Volumn 41, Issue 3, 2003, Pages 235-242

  Mukherjee, Annice ^a   Shalet, Stephen M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

BMD, final height; Childhood onset GHD; GH replacement; Peak bone mass

Indexed keywords

GROWTH HORMONE;

ADOLESCENT DISEASE; BODY GROWTH; BODY HEIGHT; BONE; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE REMODELING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHILDHOOD DISEASE; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; FINAL BODY HEIGHT; GROWTH HORMONE DEFICIENCY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; LINEAR GROWTH; LOW DRUG DOSE; ONSET AGE; OSTEOPENIA; PEAK BONE MASS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AGING; BONE DENSITY; BONE DEVELOPMENT; BONE REMODELING; FEMALE; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0042844473     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10343     Document Type: Conference Paper

References (54)

1. Kassem M, Mosekilde L, Eriksen EF. Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul 1994;4:131-135.
2. Ernst M, Froesch ER. Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I. Biochem Biophys Res Commun 1988;151:142-147.
3. Nishiyama K, Sugimoto T, Kaji H, et al. Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. Endocrinology 1996;137:35-41.
4. Chihara K, Sagimoto T. The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts. Horm Res 1997;48(Suppl 5):45-49.
5. Saggese G, Baroncelli GI, Bertelloni S, et al. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children. Pediatr Res 1994;35:409-415.
6. Boot AM, Engels MA, Boerma GJ, et al. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J Clin Endocrinol Metab 1997;82:2423-2428.
7. Brixen K, Nielsen HK, Mosekilde L, et al. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 1990;5:609-618.
8. Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 1996;81:3352-3359.
9. Baroncelli GI, Bertelloni S, Ceccarelli C, et al. Dynamics of bone turnover in children with GH deficiency treated with GH until final height. Eur J Endocrinol 2000;142:549-556.
10. Fors H, Bjarnason R, Wiren L, et al. Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents, Clin Endocrinol (Oxf) 2001;55:617-624.
11. Kaufman JM, Taelman P, Vermeulen A, et al. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992;74:118-123.
12. de Boer H, Blok GJ, van Lingen A, et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994;9:1319-1326.
13. O'Halloran D, Tsatsoulis A, Whitehouse RW, et al. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993;76:1344-1348.
14. Sartorio A, Ortolani S, Conti A, et al. Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency. J Endocrinol Invest 1996;19:524-529.
15. Holmes SJ, Economou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669-674.
16. Toogood AA, Adams JE, PA ON, et al. Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 1997;82:1462-1466.
17. Janssen YJ, Hamdy NA, Frolich M, et al. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83:2143-2148.
18. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-75.
19. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997;137:240-245.
20. Colao A, Di Somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999;84:1919-1924.
21. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 1999;16:398-405.
22. Glastre C, Braillon P, David L, et al. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: Correlations with growth parameters. J Clin Endocrinol Metab 1990;70:1330-1333.
23. Saggese G, Baroncelli GI, Bertelloni S, et al. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab 1996;81:3077-3083.
24. Baroncelli GI, Bertelloni S, Ceccarelli C, et al. Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J Clin Endocrinol Metab 1998;83:3150-3154.
25. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992;7:137-145.
26. Rahim A, Holmes SJ, Adams JE, et al. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Clin Endocrinol (Oxf) 1998;48:463-469.
27. Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxf) 1993;39:409-415.
28. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309-317.
29. Holmes SJ, Whitehouse RW, Economou G, et al. Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement. Clin Endocrinol (Oxf) 1995;42:3-7.
30. Balducci R, Toscano V, Pasquino AM, et al. Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy. Eur J Endocrinol 1995;132:42-46.
31. Ott SM. Bone density in adolescents. N Engl J Med 1991;325:1646-1647.
32. Sneppen SB, Hoeck HC, Kollerup G, et al. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults - An 18-month randomised, placebo-controlled, double blinded trial. Eur J Endocrinol 2002;146:187-195.
33. Shore RM, Chesney RW, Mazess RB, et al. Bone mineral status in growth hormone deficiency. J Pediatr 1980;96:393-396.
34. Rosen T, Hansson T, Granhed H, et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993;129:201-206.
35. Johansson AG, Burman P, Westermark K, et al. The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. J Intern Med 1992;232:447-452.
36. Fernholm R, Bramnert M, Hagg E, et al. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000;85:4104-4112.
37. Murray R, Columb B, Adams J, Shalet S. The osteopenia of adult GH deficiency is age-dependent. 20th Joint Meating of the British Endocrine Societies, 2002. p. 107.
38. Koranyi J, Svensson J, Gotherstrom G, et al. Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: A comparative, prospective study. J Clin Endocrinol Metab 2001;86:4693-4699.
39. Attie KM. The importance of growth hormone replacement therapy for bone mass in young adults with growth hormone deficiency. J Pediatr Endocrinol Metab 2000;13(Suppl 2):1011-1021.
40. Shalet SM, Clayton PE, Price DA. Growth and pituitary function in children treated for brain tumours or acute lymphoblastic leukaemia. Horm Res 1988;30:53-61.
41. Brennan BM, Rahim A, Mackie EM, et al. Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood. Clin Endocrinol (Oxf) 1998;48:777-783.
42. Murray RD, Darzy KH, Gleeson HK, et al. GH-deficient survivors of childhood cancer: GH replacement during adult life. J Clin Endocrinol Metab 2002;87:129-135.
43. Murray RD, Adams JE, Smethurst LE, et al. Spinal irradiation impairs the osteo-anabolic effects of low-dose GH replacement in adults with childhood-onset GH deficiency. Clin Endocrinol (Oxf) 2002;56:169-174.
44. Shalet SM, Gibson B, Swindell R, et al. Effect of spinal irradiation on growth. Arch Dis Child 1987;62:461-464.
45. Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest 1994;93:799-808.
46. Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporos Int 2000;11:985-1009.
47. Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991;73:555-563.
48. Bonjour JP, Theintz G, Law F, et al. Peak bone mass. Osteoporos Int 1994;4(Suppl 1):7-13.
49. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: Evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992;75:1060-1065.
50. Attanasio A, Howell S, Bates P, et al. Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinal Metab 2002;87:3368-3372.
51. Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997;82:82-88.
52. Benbassat CA, Wasserman M, Laron Z. Changes in bone mineral density after discontinuation and early reinstitution of growth hormone (GH) in patients with childhood-onset GH deficiency. Growth Horm IGF Res 1999;9:290-295.
53. ter Maaten JC, de Boer H, Kamp O, et al. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 1999;84:2373-2380.
54. Attanasio A, Cromer M, Chavrikowa E. Effect of GH treatment on bone in postpubertal GH deficient patients: A 2-year dose-ranging, controlled study. J Clin Endocrinol Metab 2003; in press.